Ivan Gergel
InvestorManaging Partner at New Rhein Healthcare Investors, LLC
Pennsylvania
Writes $100K – $5M checks · typically $1.5M
About
Ivan Gergel, MD, MBA, has been Managing Partner and Chief Medical Officer at New Rhein since 2017. A global pharmaceutical R&D executive credited with 14 drug approvals, he previously held senior roles at Nektar Therapeutics, Endo Health Solutions, Forest Laboratories, and SmithKline Beecham, and holds an MD from the University of London and an MBA from Wharton.
Invests in
Biotech
Experience
- Alveus Therapeutics IncChief Medical Officer (Interim)current2026 — presentCopenhagen, Philadelphia
- Alveus Therapeutics IncBoard Membercurrent2024 — presentCopenhagen, Philadelphia
- Corsair PharmaChairman of the Board of Directorscurrent2023 — present
- Theranica Bio-Electronics Ltd.Director Board of Directorscurrent2022 — present
- Butterfly MedicalDirector Board of Directorscurrent2020 — present
- New Rhein Healthcare InvestorsManaging Partner and Chief Medical Officercurrent2018 — presentPhiladelphia, London, Brussels
- Neuraptive TherapeuticsDirector Board of Directorscurrent2018 — present
- Travecta TherapeuticsDirector Board of Directors2021 — 2022
- Neurotrope Inc.Director Board of Directors2018 — 2020
- Realm Therapeutics, Inc.Director Board of Directors2016 — 2019
- CoriumDirector Board of Directors2014 — 2018
- Nektar TherapeuticsHead of Development & Chief Medical Officer2014 — 2017San Francisco Bay Area
- Endo PharmaceuticalsChief Scientific Officer2008 — 2014Malvern, Pennsylvania, United States
- Forest Laboratories (now Allergan)President R&D2003 — 2008New York, New York, United States
Education
- The Wharton SchoolMaster of Business Administration - MBA, Business Administration and Management
- University of LondonDoctor of Medicine - MD
- Royal College of PsychiatristsMRCPsych, Psychiatry
Skills & more
Clinical Trials25Lifesciences16Commercialization12R&D12Clinical Development11Biotechnology9Drug Development5Cross-functional Team Leadership4Clinical Research2Drug Discovery4Drug Delivery2Biopharmaceuticals3
+12 more
OncologyRegulatory AffairsTechnology TransferSopScienceInfectious DiseasesLife SciencesFDALeadershipStrategyPharmaceutical IndustryCROFrom Ivan's professional profile.
Same school
Also attended The Wharton School1,366
Fred WilsonCo-founder & Partner at Union Square VenturesJosh KopelmanFounder and Partner at First Round CapitalAydin SenkutFounder & Managing Partner at FelicisKatie RiesterPartner, Head of Investor Relations at Felicis VenturesTrevor OelschigInvestment Team at General CatalystRebecca JamesInvestor at Index Ventures
.jpeg)
+ 1,360 more
Also attended University of London82
Sandra SchwarzerInvestor at Index VenturesKarim GillaniGeneral Partner at Luge CapitalRoxanneCompliance Officer at Hummingbird VenturesRakesh MurriaCOO at Nauta CapitalJos WhiteGeneral Partner at Notion CapitalTeo Qi ShanInvestor Relations Associate at Jungle Ventures
+ 76 more
Shared employers
Also worked at Alveus Therapeutics Inc3
Also worked at Neuraptive Therapeutics1
Also worked at Realm Therapeutics, Inc.2
Also worked at Nektar Therapeutics2
Deals · 1
Neuraptive TherapeuticsBoard seat
via New Rhein Healthcare Investors, LLC · filed Oct 2022 · $38.1M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at New Rhein Healthcare Investors, LLC
Akhil Akula
Vice President at New Rhein Healthcare Investors, LLC
Amy Bevacqua
Vice President at New Rhein Healthcare Investors, LLC
Bill Engels
Chief Finance Officer at New Rhein Healthcare Investors, LLC
Chris Ferris
Head of Investor Relations at New Rhein Healthcare Investors, LLC
Clarisa Gonsalves
Executive Administrative Assistant at New Rhein Healthcare Investors, LLC
Greg Parekh
Founder and Managing Partner at New Rhein Healthcare Investors, LLC
Jonathan Soll
Associate at New Rhein Healthcare Investors, LLC
Lauren Exposito
Investor Relations Associate at New Rhein Healthcare Investors, LLC